MAPT and Alzheimer disease: Recent studiesusing ultrasensitive immunoassays have shown that plasma tau is avalid progression biomarker in AD.5 Althoughimmunoassays have high specificity and sensitivity, they exhibit substantialdisadvantages especially for quantification of heavily phosphorylatedregions of tau.